First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy
| dc.contributor.author | VandenDriessche, Thierry | |
| dc.contributor.author | Pipe, Steven W. | |
| dc.contributor.author | Pierce, Glenn F. | |
| dc.contributor.author | Kaczmarek, Radoslaw | |
| dc.contributor.department | Pediatrics, School of Medicine | |
| dc.date.accessioned | 2024-04-17T10:36:24Z | |
| dc.date.available | 2024-04-17T10:36:24Z | |
| dc.date.issued | 2022 | |
| dc.eprint.version | Final published version | |
| dc.identifier.citation | VandenDriessche T, Pipe SW, Pierce GF, Kaczmarek R. First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy. Mol Ther. 2022;30(11):3335-3336. doi:10.1016/j.ymthe.2022.09.020 | |
| dc.identifier.uri | https://hdl.handle.net/1805/40073 | |
| dc.language.iso | en_US | |
| dc.publisher | Elsevier | |
| dc.relation.isversionof | 10.1016/j.ymthe.2022.09.020 | |
| dc.relation.journal | Molecular Therapy | |
| dc.rights | Publisher Policy | |
| dc.source | PMC | |
| dc.subject | Drug approval | |
| dc.subject | Genetic therapy | |
| dc.subject | Hemophilia A | |
| dc.title | First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy | |
| dc.type | Article | |
| ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637642/ |